Q-omics provides the consensus-scored NAA15 profile across patient tissues and cancer cell-line models. NAA15 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, NAA15 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, NAA15 protein abundance shows 24,554 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight LIHC, KIRC, and LUAD as cancer lineages where NAA15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NAA15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NAA15 survival associations across molecular data types. NAA15 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NAA15 RNA expression–survival associations across cancer types. High NAA15 expression shows unfavorable associations in LIHC, KIRP, UVM and MESO, but favorable associations in KIRC and READ. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for NAA15 RNA expression.
This table summarizes NAA15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NAA15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NAA15 shows lower tumor expression in THCA and higher tumor expression in KIRC, LUAD, STAD, LIHC and COAD. The KIRC box plot shows higher NAA15 RNA expression in tumor versus normal tissue (log2 FC = +0.625, t-test p < 0.001).
This table shows molecular features associated with NAA15 in patient tissues and cancer cell lines. In patient samples, NAA15 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NAA15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
